The association between plasma C-peptide concentration and the risk of prostate cancer: a nested case-control study within a Japanese population-based prospective study.
The association between plasma C-peptide concentration and the risk of prostate cancer: a nested case-control study within a Japanese population-based prospective study.
复制标题
血浆 C 肽浓度与前列腺癌风险之间的关联：日本基于人群的前瞻性研究中的一项巢式病例对照研究。
DOI：
10.1097/cej.0000000000000363
复制
发表时间：
2017
期刊：
影响因子：
--
通讯作者：
Tsugane S; JPHC Study Group
中科院分区：
文献类型：
--
作者：
Kiyabu GY;Sawada N;Iwasaki M;Yamaji T;Shimazu T;Sasazuki S;Inoue M;Tsugane S; JPHC Study Group
血浆 C 肽浓度与前列腺癌之间的关联尚不清楚。先前研究结果的不一致激发了这项研究。利用基于日本公共卫生中心的前瞻性研究，201 名前列腺癌病例和 402 名对照者根据年龄、公共卫生中心区域、居住地、采血日期和时间以及采血前的禁食时间进行了匹配。通过条件逻辑回归模型估计优势比 (OR) 和 95% 置信区间 (CI)。在 201 例病例中，144 例为局限性病例，48 例为晚期病例。中位血浆 C 肽浓度与前列腺癌之间的总体关联并不显着（最高三分位数的 OR = 0.81，95% CI：0.43–1.56，P 趋势 = 0.54）。虽然前列腺癌按分期分层表明血浆 C 肽对局部和晚期病例有不同的影响，但血浆 C 肽浓度与晚期前列腺癌（最高类别 OR = 2.82，95% CI：0.30–26.36，P 趋势 = 0.37）和局部病例（最高类别 OR = 0.49，95% CI：0.23–1.04）之间没有关联。类别，P-趋势 = 0.06），适用于采血时禁食的患者。血浆 C 肽浓度与前列腺癌风险之间的关联因癌症阶段而异。在研究血浆 C 肽浓度与前列腺癌风险之间的关联时，区分局部和晚期前列腺癌病例至关重要。
The association between plasma C-peptide concentration and prostate cancer is unclear. Inconsistency of results from previous studies motivates this study. Using the Japan Public Health Center-based Prospective study, 201 prostate cancer cases and 402 controls were matched by age, public health center area, residence, date and time of blood collection, and fasting duration before blood collection. Odds ratios (OR) and 95% confidence intervals (CIs) were estimated by conditional logistic regression models. Out of 201 cases, 144 were localized and 48 were advanced. The overall association between median plasma C-peptide concentration and prostate cancer was not significant (OR for the highest tertile= 0.81, 95% CI: 0.43–1.56, P-trend= 0.54). Although stratification of prostate cancer by stage indicated different effects of plasma C-peptide on localized and advanced cases, there was no association between plasma C-peptide concentration and advanced prostate cancer (OR= 2.82, 95% CI: 0.30–26.36 for the highest category, P-trend= 0.37) and localized cases (OR= 0.49, 95% CI: 0.23–1.04 for the highest category, P-trend= 0.06) for patients fasting at the time of blood collection. The association between plasma C-peptide concentration and prostate cancer risk differed by cancer stage. Differentiation of localized and advanced prostate cancer cases is crucial when investigating the association between plasma C-peptide concentration and the risk of prostate cancer.